HC Wainwright Has Bearish Forecast for ACXP FY2026 Earnings

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) – Equities research analysts at HC Wainwright cut their FY2026 earnings estimates for Acurx Pharmaceuticals in a report released on Thursday, November 12th. HC Wainwright analyst M. Keller now expects that the company will post earnings per share of ($2.03) for the year, down from their previous forecast of ($2.00). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2026 earnings at ($0.46) EPS and FY2027 earnings at ($1.66) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11).

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

Read Our Latest Stock Analysis on ACXP

Acurx Pharmaceuticals Stock Performance

Shares of NASDAQ:ACXP opened at $0.96 on Monday. Acurx Pharmaceuticals has a 12-month low of $0.92 and a 12-month high of $7.54. The business’s fifty day simple moving average is $1.22 and its 200-day simple moving average is $1.90. The company has a market capitalization of $5.34 million, a PE ratio of -0.49 and a beta of -2.08.

About Acurx Pharmaceuticals

(Get Free Report)

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing antibiotics to treat bacterial infections, particularly those caused by Gram-positive bacteria. The company’s research centers on DNA polymerase IIIC inhibitors, a class designed to interfere with bacterial DNA replication. Its lead investigational candidate, ibezapolstat, is being developed to treat infections caused by Clostridioides difficile (C. difficile). Acurx has also pursued other antibiotic candidates for Gram-positive bacterial infections.

See Also

Earnings History and Estimates for Acurx Pharmaceuticals (NASDAQ:ACXP)

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.